期刊
SEMINARS IN IMMUNOPATHOLOGY
卷 39, 期 4, 页码 487-500出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00281-017-0623-3
关键词
Rheumatoid arthritis; GM-CSF; JAK; BTK; PI3K; Tolerogenic dendritic cells
资金
- AbbVie
- BMS
- Janssen
- Novartis
- Pfizer
- Roche
- UCB
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment. With the implementation of treat-to-target strategies and availability of biologic therapies, the outcomes for patients with RA have significantly improved. However, the unmet need in the treatment of RA remains high as some patients do not respond sufficiently to the currently available agents, remission is not always achieved and refractory disease is not uncommon. With better understanding of the pathophysiology of RA, new therapeutic approaches are emerging. Apart from more selective Janus kinase inhibition, there is a great interest in the granulocyte macrophage-colony stimulating factor pathway, Bruton's tyrosine kinase pathway, phosphoinositide-3-kinase pathway, neural stimulation and dendritic cell-based therapeutics. In this review, we will discuss the therapeutic potential of these novel approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据